NCT02223026View on ClinicalTrials.gov

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

Linagliptin/metformin FDC

OTHER

high-fat, high caloric meal

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02223026 - Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter